Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer
Status:
Active, not recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
Ovarian cancer was mostly diagnosed at late stage (III/IV) with high rate of recurrence after
first line of therapy by optimal cytoreductive sugery and 6-8cycle of TP chemotherapy. We
developed an adjuvant chemotherapy of "three steps" (ACTS). It is adding CTX+VP-16(second
step)6cycle and CTX+CBP(third steps) to firstline chemotherapy (first step). The aim of this
study is to verify the effectivity and safety of ACTS.